WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Cent ...

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting ...

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [4] - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive therapies [4] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [4] Recent Developments - The company will report its first-quarter results for the period ended March 31, 2025, and provide business updates on May 12, 2025, after market close [1] - A conference call for investors is scheduled for May 13, 2025, at 8:00 a.m. ET, with a live webcast available on the company's website [2] Product Pipeline - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [4] - The company is also developing an earlier-stage epinephrine prodrug topical gel for dermatological conditions such as alopecia areata [4]